Home Facilities Facility Custom Antibody Service (CAbS)
  • S08 - Immunochemical Methods Development

    CAbS offers personalized development of immunoassays. Antibodies and other necessary immunoreagents can be synthesized.


    The development of the immunoassay includes various stages:

    1. Design of the immunoassay format, sample matrix, the sensitivity and the working range. Identification of necessary reagents and their conditions to obtain optimal results.
    2. Development phase: Establishing assay parameters such as the detection limit and working range. Evaluation of the effects of the matrix on the assay reproducibility study.
    3. Assay validation: Evaluation of the stability and robustness of the reagents. Measurement of inter and intra-assay reproducibility, precision and specificity. Validation with blind samples.
    4. Assay platform: ELISA, microarray with different formats based on the detection of individual analytes or multiplexed assays. 

  • S07 - Antibody Purification

    The purification of the antibodies includes the isolation of the antibody from the serum (polyclonal antibodies) or culture supernatant from hybridoma cell line (monoclonal antibodies). CAbS offers previous advise on the different possibilities for purification according to the needs of the user.


    The methods of purification that we offer vary from crude methods (precipitation of the proteins from the sample including any antibody present) to general purification (purification by affinity of certain classes of antibodies without taking account of the specificity to the antigen) to specific purification (by affinity of the antibodies that join specifically to the definite antigen). 


    • Ammonium sulphate precipitation
    • Protein A, protein G affinity purification
    • Specific antigen affinity purification

  • S06 - Hybridoma Cell Culture Antibody Production

    Hybridoma cell culture in ultralow serum medium. We use CELLine™ Bioreactor Technology to produce monoclonal antibodies.

  • S05 - Monoclonal Antibody Development

    The mAb development contains the following phases:

    1. Immunization of mice, titer determination of the antiserum.
    2. Cultivation of the myeloma cell line, cell fusion, selection in HAT medium and screening.
    3. Cloning, screening and cultivation of positive cultures. Further cloning and obtaining of stable clones.
    4. Expansion and cryopreservation of the selected clones. Delivery of cell culture supernatants and frozen hybridoma cells. 

  • S04 - Polyclonal Antibody Production

    The service has a standard immunization protocol that includes monthly inoculations with Freund's adjuvant during a period of 4 months. This protocol can be adapted to the final objective of the project.


    To determine the progress of the immune response a bleed is taken 10 days after the second immunization to obtain antiserum and the titer is determined by ELISA.


    Among the controls is the obtaining of preimmune serum from the animalsbefore the first injection. At the end of the process 50-70 ml of the hyperimmune serum is obtainedper animal from the final bleed.

  • S03 - Preparation of Bioconjugates and Molecular Probes

    Protein and hapten conjugation services with different types of molecules such as enzymes, fluorophores, biotin, KLH, BSA, gold particles, magentic particles, nanotubes etc.


    Preparation of antibody fragments. 

  • S02 - Hapten Synthesis

    Selection of suitable leading structures for antigen preparation, hapten synthesis, hapten modification and derivation.

  • S01 - Scientific and Technical Support

    Scientific and technical support and advice on immunogen design, immunoreagent synthesis and production, antibody production and immunoassay design and development.

    Staff: Dr. Nuria Pascual Ana González Pablo Martínez